Traumatic Brain Injury News and Research

RSS
Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue. Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking. A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.
Banyan Biomarkers completes $6 million series A funding for further biomarker research

Banyan Biomarkers completes $6 million series A funding for further biomarker research

Targeted mental workouts can sharpen memory, improve cognitive function in schizophrenia

Targeted mental workouts can sharpen memory, improve cognitive function in schizophrenia

Combination of two proteins released after head injury might be best way to diagnose MTBI

Combination of two proteins released after head injury might be best way to diagnose MTBI

Study shows brain abnormalities in MTBI patients closely resemble Alzheimer's dementia

Study shows brain abnormalities in MTBI patients closely resemble Alzheimer's dementia

Study offers hope for development of novel treatments for stroke, neurological diseases

Study offers hope for development of novel treatments for stroke, neurological diseases

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

Kessler Foundation receives grants from NJ Commission to study deficits in TBI patients

Kessler Foundation receives grants from NJ Commission to study deficits in TBI patients

Brain-training computer games may help restore memory and competency to forensic psychiatry patients

Brain-training computer games may help restore memory and competency to forensic psychiatry patients

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

NeuroVive Pharmaceutical recruits first traumatic brain injury patient to evaluate NeuroSTAT

NeuroVive Pharmaceutical recruits first traumatic brain injury patient to evaluate NeuroSTAT

Study suggests bright light therapy may improve sleep and brain function post mild TBI

Study suggests bright light therapy may improve sleep and brain function post mild TBI

Researchers tie traumatic brain injury to toxic form of protein

Researchers tie traumatic brain injury to toxic form of protein

Non-invasive brain stimulation techniques improve memory

Non-invasive brain stimulation techniques improve memory

Spontaneous brain activity in amygdala higher among combat veterans with PTSD

Spontaneous brain activity in amygdala higher among combat veterans with PTSD

Fall-induced traumatic brain injury is major cause of disability and death among older adults, says research

Fall-induced traumatic brain injury is major cause of disability and death among older adults, says research

TBI in older adults presents special diagnostic, management and treatment challenges

TBI in older adults presents special diagnostic, management and treatment challenges

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Research reveals that molecular madness goes on in the brain after blast exposure

Research reveals that molecular madness goes on in the brain after blast exposure

Astrocytes more effective in promoting recovery after brain injury

Astrocytes more effective in promoting recovery after brain injury

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.